Physician profile
Lucy Graubard
NPI 1639252984
$1,633.63
in general payments reported to CMS, 2019-2025
25 companies · $544 in 2025
The $544 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $118 · 2021: $132 · 2022: $232 · 2023: $164 · 2024: $262 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $210.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $167.75 | 2019-2025 | Vaxneuvance, Vaxelis, Rotateq |
| Cranial Technologies, INC | $167.68 | 2019-2025 | Doc Band |
| Dermavant Sciences, INC. | $124.40 | 2022 | |
| Organon LLC | $124.40 | 2025 | Vtama |
| Pfizer INC. | $110.21 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $100.04 | 2025 | |
| Kyowa Kirin, INC. | $84.44 | 2025 | |
| Seqirus USA INC | $80.08 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Phadia US INC. | $43.73 | 2019 | |
| Sun Pharmaceutical Industries INC. | $42.40 | 2023 | Absorica Ld, Winlevi |
| Glaxosmithkline, LLC. | $41.25 | 2022-2025 | Bexsero |
| Ironshore Pharmaceuticals INC. | $38.03 | 2020 | |
| Ucb, INC. | $37.98 | 2024 | Nayzilam |
| Shire North American Group INC | $36.76 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.22 | 2020 | |
| Biomarin Pharmaceutical INC. | $31.11 | 2025 | Voxzogo 1.2mg |
| Takeda Pharmaceuticals U.S.A., INC. | $23.50 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.20 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals Lp | $20.70 | 2023 | Flumist Quadrivalent |
| Novartis Pharmaceuticals Corporation | $20.37 | 2019 | |
| Coloplast Corp | $19.79 | 2022 | |
| Sobi, INC | $18.48 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.82 | 2020 | |
| Tris Pharma INC | $16.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Graubard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.